{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:59:40Z","timestamp":1791554380184,"version":"4.3.4"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Patients with chronic pain often receive long-term opioid therapy (LOT), which places them at risk of opioid use disorder and overdose. This presents the need for alternative or companion treatments; however, few studies on the association of medical cannabis (MC) with reducing opioid dosages exist.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess changes in opioid dosages among patients receiving MC for longer duration compared with shorter duration.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study of New York State Prescription Monitoring Program data from 2017 to 2019 included patients receiving MC for chronic pain while also receiving opioid treatment. Of these, patients receiving LOT prior to receiving MC were selected. Individuals were studied for 8 months after starting MC. Data were analyzed from November 2021 to February 2022.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Selected patients were divided into 2 groups based on the duration of receiving MC: the nonexposure group received MC for 30 days or fewer, and the exposure group received MC for more than 30 days.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was opioid dosage, measured by mean daily morphine milligram equivalent (MME). Analyses were conducted for 3 strata by opioid dosage prior to receiving MC: MME less than 50, MME of 50 to less than 90, and MME of 90 or greater.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 8165 patients were included, with 4041 (median [IQR] age, 57 [47-65] years; 2376 [58.8%] female) in the exposure group and 4124 (median [IQR] age, 54 (44-62) years; 2370 [57.5%] female) in the nonexposure group. Median (IQR) baseline MMEs for the exposure vs nonexposure groups were 30.0 (20.0-40.0) vs 30.0 (20.0-40.0) in the lowest stratum, 60.0 (60.0-70.0) vs 60.0 (60.0-90.0) in the middle stratum, and 150.0 (100.0-216.2) vs 135.0 (100.0-218.0) in the highest stratum. During follow-up, significantly greater reductions in opioid dosage were observed among the exposure group. A dose-response association of patients\u2019 opioid dosage at baseline was observed with the differences in the monthly MME reductions between exposure and nonexposure groups, with a difference of \u22121.52 (95% CI, \u22121.67 to \u22121.37) MME for the lowest stratum, \u22123.24 (95% CI, \u22123.61 to \u22122.87) MME for the middle stratum, and \u22129.33 (95% CI, \u22129.89 to \u22128.77) MME for the highest stratum. The daily MME for the last month of the follow-up period among patients receiving longer MC was reduced by 48% in the lowest stratum, 47% in the middle stratum, and 51% in the highest stratum compared with the baseline dosages. Among individuals in the nonexposure group, daily MME was reduced by only 4% in the lowest stratum, 9% in the middle stratum, and 14% in the highest stratum.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients receiving LOT, receiving MC for a longer duration was associated with reductions in opioid dosages, which may lower their risk of opioid-related morbidity and mortality.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.54573","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T11:12:39Z","timestamp":1675077159000},"page":"e2254573","source":"Crossref","is-referenced-by-count":33,"title":["Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019"],"prefix":"10.1001","volume":"6","author":[{"given":"Trang","family":"Nguyen","sequence":"first","affiliation":[{"name":"New York State Department of Health, Albany"},{"name":"Department of Epidemiology and Biostatistics, University at Albany School of Public Health, Rensselaer, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshu","family":"Li","sequence":"additional","affiliation":[{"name":"New York State Department of Health, Albany"},{"name":"Department of Epidemiology and Biostatistics, University at Albany School of Public Health, Rensselaer, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Greene","sequence":"additional","affiliation":[{"name":"City University of New York Graduate School of Public Health and Health Policy, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Stancliff","sequence":"additional","affiliation":[{"name":"New York State Department of Health, Albany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Quackenbush","sequence":"additional","affiliation":[{"name":"New York State Office of Cannabis Management, Albany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"issue":"5","key":"zoi221543r4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bju.2018.122.issue-5","article-title":"The United States opioid epidemic: a review of the surgeon\u2019s contribution to it and health policy initiatives.","volume":"122","author":"Theisen","year":"2018","journal-title":"BJU Int"},{"issue":"390","key":"zoi221543r5","first-page":"1","article-title":"Chronic pain and high-impact chronic pain among U.S. adults, 2019.","author":"Zelaya","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"162","key":"zoi221543r6","first-page":"1","article-title":"Prescription opioid use among adults with chronic pain: United States, 2019.","author":"Dahlhamer","year":"2021","journal-title":"Natl Health Stat Report"},{"issue":"1","key":"zoi221543r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016.","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"zoi221543r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10754-021-09307-4","article-title":"Opioid and non-opioid analgesic prescribing before and after the CDC\u2019s 2016 opioid guideline.","volume":"22","author":"Encinosa","year":"2022","journal-title":"Int J Health Econ Manag"},{"key":"zoi221543r9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40266-019-00660-1","article-title":"Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say?","volume":"36","author":"Cooper","year":"2019","journal-title":"Drugs Aging"},{"issue":"6","key":"zoi221543r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16726","article-title":"Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering.","volume":"5","author":"Fenton","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi221543r11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pmn.2019.06.009","article-title":"Cannabis use motivations among adults prescribed opioids for pain versus opioid addiction.","volume":"21","author":"Clem","year":"2020","journal-title":"Pain Manag Nurs"},{"issue":"7","key":"zoi221543r12","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2468-2667(18)30110-5","article-title":"Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study.","volume":"3","author":"Campbell","year":"2018","journal-title":"Lancet Public Health"},{"issue":"58","key":"zoi221543r14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/jncimonographs\/lgab009","article-title":"Challenges for clinical cannabis and cannabinoid research in the United States.","volume":"2021","author":"Cooper","year":"2021","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"zoi221543r15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13643-020-01425-3","article-title":"Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review.","volume":"9","author":"Okusanya","year":"2020","journal-title":"Syst Rev"},{"issue":"7","key":"zoi221543r16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41386-022-01322-4","article-title":"Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.","volume":"47","author":"Nielsen","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"zoi221543r17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1186\/s12889-021-10867-w","article-title":"Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.","volume":"21","author":"Lee","year":"2021","journal-title":"BMC Public Health"},{"issue":"11","key":"zoi221543r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187795","article-title":"Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study.","volume":"12","author":"Vigil","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"zoi221543r24","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","article-title":"Patient adherence and medical treatment outcomes: a meta-analysis.","volume":"40","author":"DiMatteo","year":"2002","journal-title":"Med Care"},{"issue":"3","key":"zoi221543r25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"zoi221543r26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/1536867X0800800405","article-title":"Erratum and discussion of propensity-score reweighting.","volume":"8","author":"Nichols","year":"2008","journal-title":"Stata J"},{"issue":"6","key":"zoi221543r27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/jep.2011.17.issue-6","article-title":"Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation.","volume":"17","author":"Linden","year":"2011","journal-title":"J Eval Clin Pract"},{"issue":"4","key":"zoi221543r28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"zoi221543r29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003567","article-title":"Use of interrupted time series methods in the evaluation of health system quality improvement interventions: a methodological systematic review.","volume":"5","author":"Hategeka","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"5","key":"zoi221543r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4514","article-title":"Indication-specific opioid prescribing for US patients with Medicaid or private insurance, 2017.","volume":"3","author":"Mikosz","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi221543r32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054282","article-title":"Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies.","volume":"12","author":"Zeraatkar","year":"2022","journal-title":"BMJ Open"},{"key":"zoi221543r33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/IJGM.S275049","article-title":"Safety considerations in cannabinoid-based medicine.","volume":"13","author":"Gottschling","year":"2020","journal-title":"Int J Gen Med"},{"issue":"3","key":"zoi221543r34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1098214014527337","article-title":"Examining the internal validity and statistical precision of the comparative interrupted time series design by comparison with a randomized experiment.","volume":"35","author":"St.Clair","year":"2014","journal-title":"Am J Eval"},{"issue":"3","key":"zoi221543r35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3102\/1076998616636854","article-title":"The validity and precision of the comparative interrupted time-series design: three within-study comparisons.","volume":"41","author":"St.Clair","year":"2016","journal-title":"J Educ Behav Stat"},{"key":"zoi221543r1","unstructured":"National Center for Injury Prevention and Control. Understanding the Opioid Epidemic. Centers for Disease Control and Prevention. Accessed May 1, 2022. https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html?"},{"key":"zoi221543r2","unstructured":"Centers for Disease Control and Prevention. CDC WONDER: about provisional mortality statistics, 2018 through last month. Accessed May 1, 2022. https:\/\/wonder.cdc.gov\/mcd-icd10-provisional.html"},{"key":"zoi221543r3","unstructured":"Centers for Disease Control and Prevention. US opioid dispensing rate maps. Accessed May 1, 2022. https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html"},{"key":"zoi221543r13","unstructured":"Agency for Healthcare Research and Quality. Systematic review: living systematic review on cannabis and other plant-based treatments for chronic pain. Updated September 2022. Accessed December 1, 2022. https:\/\/effectivehealthcare.ahrq.gov\/products\/plant-based-chronic-pain-treatment\/living-review"},{"key":"zoi221543r18","unstructured":"New York State Medical Cannabis Program. Accessed May 1, 2022. https:\/\/cannabis.ny.gov\/medical-cannabis"},{"key":"zoi221543r19","unstructured":"S7923. 2013-2014 Session (NY 2014). Accessed May 1, 2022. https:\/\/www.nysenate.gov\/legislation\/bills\/2013\/S7923"},{"key":"zoi221543r20","unstructured":"Section 1004.2\u2014Practitioner issuance of certification. NY Pub Health Law, \u00a73360 and 3369-a (2019). Accessed May 1, 2022. https:\/\/regs.health.ny.gov\/content\/section-10042-practitioner-issuance-certification"},{"key":"zoi221543r21","unstructured":"New York State Department of Health; Bureau of Narcotic Enforcement. I-STOP\/PMP: Internet System for Tracking Over-Prescribing\u2014Prescription Monitoring Program. Accessed May 1, 2022. https:\/\/www.health.ny.gov\/professionals\/narcotic\/prescription_monitoring\/"},{"key":"zoi221543r23","unstructured":"Part 80\u2014rules and regulations on controlled substances. NY Pub Health Law \u00a7338, 3300, 3305, 3307, 3308, 3309, 3381, 3701(1), (6), art. 33. Accessed May 1, 2022. https:\/\/regs.health.ny.gov\/content\/section-8067-schedule-ii-and-certain-other-substances"},{"key":"zoi221543r31","doi-asserted-by":"crossref","unstructured":"Chou? R, Wagner? J, Ahmed? AY, . Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain. Updated September 2022. Accessed December 1, 2022. https:\/\/effectivehealthcare.ahrq.gov\/products\/plant-based-chronic-pain-treatment\/living-review","DOI":"10.23970\/AHRQEPCCER250.2022UPDATESR1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800813\/nguyen_2023_oi_221543_1674058859.69155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T11:12:47Z","timestamp":1675077167000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54573","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]}}}